Fresenius stock gains before Q3 results after WuXi deal

Fresenius stock traded at 48.76 euros on Lang & Schwarz at 12:30 CET on Tuesday, November 3, 0.37 percent above the Xetra close of Monday, November 2. The healthcare group is heading into its third-quarter report after announcing a major expansion of its biosimilars pipeline.

On November 2, Fresenius announced an exclusive development agreement with WuXi Biologics. The company receives access to up to 37 identified biosimilar candidates over the next decade, while retaining exclusive global commercialization rights and the full economics of products it brings to market. PR Newswire published the company announcement on the same day.

WuXi broadens the Biopharma platform

Fresenius said the agreement could expand its marketed and pipeline portfolio from 29 molecules to as many as 66 over the next decade. The candidates address more than 370 billion euros in originator list-price-based sales, a reference to the markets served by the original medicines rather than projected Fresenius revenue.

The potential portfolio spans 13 therapeutic areas and includes monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Initial development is expected to focus on polatuzumab vedotin, an antibody-drug conjugate used in large B-cell lymphoma, and teprotumumab, a monoclonal antibody used in thyroid eye disease.

Fresenius will select candidates according to market attractiveness, development risk and expected returns. WuXi will be compensated on a fee-for-service basis for each selected program. Fresenius said development spending will rise as programs advance, before any future revenue and profitability from successful products. The company will decide the long-term manufacturing strategy for each candidate, including possible transfers to its wholly owned mAbxience network.

Chief Executive Michael Sen said Fresenius was increasing its commitment to Biopharma while keeping economic ownership, strategic control and capital allocation flexibility. The agreement is funded from operating cash flow and requires no new financing, according to the company.

Q3 report is the next catalyst

Fresenius kept its full-year 2026 guidance unchanged and confirmed its existing 2030 ambition to approximately double Biopharma revenue from the 2025 level at an EBIT margin of around 20 percent. The company said the WuXi agreement expands the opportunity beyond that existing ambition and that it expects to raise its longer-term Biopharma targets.

Fresenius is scheduled to publish its third-quarter 2026 results on Wednesday, November 4. The management webcast is scheduled for 1:30 p.m. CET, according to Fresenius investor relations. The report will give investors the next regular read-through on operating performance and the group outlook.

Investors should distinguish the pipeline potential from near-term earnings: Fresenius must exercise options candidate by candidate, and the company cautioned that not every program will be developed or reach the market. The unchanged guidance provides the immediate financial frame, while the agreement increases the strategic scope of the Biopharma business beyond 2030.

For the broader German market context, see the current DAX market environment.

Follow the real-time quote of Fresenius stock for the latest trading level.

More news and analyses on Fresenius stock.